These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25064437)

  • 21. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
    Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
    Foster GR; Hézode C; Bronowicki JP; Carosi G; Weiland O; Verlinden L; van Heeswijk R; van Baelen B; Picchio G; Beumont M
    Gastroenterology; 2011 Sep; 141(3):881-889.e1. PubMed ID: 21699786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
    Hayashi N; Mobashery N; Izumi N
    J Gastroenterol; 2015 Feb; 50(2):238-48. PubMed ID: 25115901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
    Sandoval-Ramirez JL; Mata-Marín JA; Huerta García G; Gaytán-Martínez JE
    J Infect Dev Ctries; 2015 Mar; 9(3):267-73. PubMed ID: 25771464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.
    Fredlund P; Hillson J; Gray T; Shemanski L; Dimitrova D; Srinivasan S
    J Interferon Cytokine Res; 2015 Nov; 35(11):841-3. PubMed ID: 26376344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
    Marcellin P; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Serfaty L; De Backer K; Van Heeswijk R; Luo D; Picchio G; Beumont M
    Gastroenterology; 2011 Feb; 140(2):459-468.e1; quiz e14. PubMed ID: 21034744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
    Foster GR; Coppola C; Derbala M; Ferenci P; Orlandini A; Reddy KR; Tallarico L; Shiffman ML; Ahlers S; Bakalos G; Hassanein T;
    PLoS One; 2016; 11(3):e0151703. PubMed ID: 27018988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
    Hézode C; Hirschfield GM; Ghesquiere W; Sievert W; Rodriguez-Torres M; Shafran SD; Thuluvath PJ; Tatum HA; Waked I; Esmat G; Lawitz EJ; Rustgi VK; Pol S; Weis N; Pockros PJ; Bourlière M; Serfaty L; Vierling JM; Fried MW; Weiland O; Brunetto MR; Everson GT; Zeuzem S; Kwo PY; Sulkowski M; Bräu N; Hernandez D; McPhee F; Wind-Rotolo M; Liu Z; Noviello S; Hughes EA; Yin PD; Schnittman S
    Gut; 2015 Jun; 64(6):948-56. PubMed ID: 25080450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
    Sarrazin C; Shiffman ML; Hadziyannis SJ; Lin A; Colucci G; Ishida H; Zeuzem S
    J Hepatol; 2010 Jun; 52(6):832-8. PubMed ID: 20385421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.